Showing results (61-70 of 584) with videos related to
Sort By:
Pageof 59
Bulletin Du Cancer|February 5, 2013
[Brain metastases of non small cell lung cancers: systemic treatments]Marie Chaubet-Houdu, Benjamin BesseEuropean Respiratory Review : an Official Journal of the European Respiratory Society|December 2, 2015
Second-line combination therapies in nonsmall cell lung cancer without known driver mutationsMaria-Virginia Bluthgen, Benjamin BesseNature Communications|September 2, 2021
Integrin-α<sub>V</sub>-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockadeInes Malenica, Julien Adam, Stéphanie Corgnac, et al.JAMA Network Open|September 10, 2025
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung CancerAdrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, et al.Clinical and Translational Radiation Oncology|May 19, 2023
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancerAntonin Levy, Jonathan Khalifa, Etienne Martin, et al.Lung Cancer (Amsterdam, Netherlands)|June 13, 2022
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directionsMariona Riudavets, Priscilla Cascetta, David PlanchardCancer|June 1, 2026
Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going?Claudia Parisi, Fabrice Barlesi, David PlanchardJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancerEmma Pailler, Julien Adam, Amélie Barthélémy, et al.Frontiers in Immunology|November 10, 2022
Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case reportMihaela Aldea, Rakiba Belkhir, Emeline Colomba, et al.Drugs|January 31, 2026
First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?Pamela Abdayem, Claudia Parisi, David PlanchardPageof 59